Moderna, Inc. MRNA
215.02 USD -8.35 (-3.74%)
As ofNov 16, 2026, 1:29 PM EST
212.50 Day range 220.59
22.36 52-week range 269.00
- YTD
- +629.12%
- 1 year
- +768.06%
News
zacks.com Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.
defenseworld.net Moderna, Inc. $MRNA Stock Sold by Commonwealth Equity Services LLC Commonwealth Equity Services LLC lowered its stake in Moderna, Inc. (NASDAQ: MRNA) by 17.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange…
barrons.com BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy. BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
marketbeat.com Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook Moderna NASDAQ: MRNA is preparing to seek U.S. approval of its individualized cancer treatment intismeran by year-end, with executives aiming for a 2027 launch alongside partner Merck if regulators…
zacks.com MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock? Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.
fool.com Why Moderna Stock Dropped on Thursday Moderna's revenue guidance for 2026 falls short of analyst targets, meaning a sales miss may be coming. Moderna's earnings might surprise to the upside if its cost-cutting pays off.
barrons.com Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes. The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine.
benzinga.com Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities Moderna raises its 2026 revenue forecast to 15%-25% and accelerates oncology investments, expanding its mRNA platform into new therapies.benzinga.com Moderna Raises FY26 Sales Growth Guidance To 15%-25% From 10%; On Track To Achieve FY26 Gross Margin Expansion Of ~10 Percentage Points Excluding Litigation Settlement Charge; Expects Annual Cash Costs Of ~$4B-$4.5B Over 2027-2030; Sees Ending 2026 With ~$9B In Total Liquidity, Including Cash, Investments And Undrawn Borrowing Capacity Moderna, Inc. (NASDAQ:MRNA) today outlined the next phase of growth at its 2026 Analyst Day, highlighting how more than a decade of investment in the Company's mRNA platform has enabled the…
benzinga.com Moderna Highlights JAMA Publication Of Real-World Comparative Effectiveness Data For COVID-19 Vaccine Adults Aged 65 Years and Older Real-world analysis of more than 294,000 U.S. Veterans aged 65 and older found mNEXSPIKE was associated with a 35.9% lower risk of medically attended COVID-19 and a 47% lower risk of…
defenseworld.net 71 West Capital Partners Acquires New Holdings in Moderna, Inc. $MRNA 71 West Capital Partners bought a new stake in shares of Moderna, Inc. (NASDAQ: MRNA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The…
fool.com Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy Moderna's revenue came in better than expected last quarter, and the company raised its guidance. Nearly all of its revenue comes from COVID-related products.
zacks.com Can Moderna's First Cancer Therapy Win FDA Approval in 2027? MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.benzinga.com Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $195 Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $137 to $195.
benzinga.com Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $305 Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $230 to $305.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
zacks.com Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology MRNA raises its 2026 revenue growth outlook after strong Q3 results, lower costs and respiratory vaccine gains, while advancing its oncology pipeline.
fool.com BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. BioNTech and Moderna are working to reduce their dependence on COVID-19 vaccines through expanding pipelines in cancer treatment and other diseases. Moderna's latest quarterly results showed…
benzinga.com Moderna Stuns Wall Street With Surprise Profit, Raises Outlook Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
benzinga.com Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
benzinga.com Moderna Q3 2026 Earnings Call Transcript Moderna (NASDAQ:MRNA) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Moderna Raises FY2026 Sales Guidance from $2.138B to $2.236B-$2.430B vs $2.102B Est Moderna (NASDAQ:MRNA) raises FY2026 sales outlook from $2.138 billion to $2.236 billion-$2.430 billion vs $2.102 billion estimate.
benzinga.com Moderna Q3 EPS $0.38 Beats $(1.26) Estimate, Sales $1.313B Beat $885.051M Estimate Moderna (NASDAQ:MRNA) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $(1.26) by 130.16 percent. This is a 174.51 percent increase over losses of $(0.51)…
benzinga.com Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Moderna reports Q3 earnings Friday, with analysts expecting a $1.25 loss per share and $890M revenue; shares fell 6.6% after vaccine approvals.
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds hit 62% as Wall Street eyes jobs data and a tech rebound.benzinga.com Moderna Says Health Canada Authorizes mFLUSIVA And mCOFLU For Adults 50 Years Of Age And Older Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®CAMBRIDGE, MA / ACCESS Newswire /…
benzinga.com Enbridge, Moderna On Deck Friday As Demand, Vaccine Pipeline Face Test Enbridge headlines Friday’s reports, with investors weighing whether resilient pipeline utilization can offset a softer revenue comparison. Moderna, Brookfield Asset Management, Humana, Vistra, PPL,…benzinga.com Moderna's Data From Its Current Phase 1/2 Trial Of mRNA-2808 Selected For Oral Presentation At 68th American Society Of Hematology Annual Meeting Moderna, Inc. (NASDAQ:MRNA) today announced that initial clinical data from its ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of…
benzinga.com Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday U.S. stocks surged, led by Wayfair after strong results; Cricut, Array Technologies, Clear Secure and others also posted double-digit gains.
benzinga.com Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop? Tempus AI, a company that Cathie Wood has invested in, will publish its financial results this week as its volatility continues.
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
benzinga.com Merck One of Top Large-Cap Biopharma Picks-Analyst Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
benzinga.com This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.
benzinga.com William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Run Moderna shares are trading lower Tuesday after William Blair downgraded the stock to Market Perform on Monday, citing valuation concerns.benzinga.com Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $230 Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $167 to $230.
benzinga.com Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing Moderna’s stock went on a wild ride last week that included a data leak and a dramatic tale from a social media influencer.
benzinga.com MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).
benzinga.com Moderna Stock Slides Again Friday: What's Going On? Moderna slides in premarket trading post ESMO data leak, despite Phase 3 vaccine trial showing a 42% cut in melanoma recurrence.
benzinga.com Deckers Outdoor Posts Mixed Q2 Results, Joins BayCom, Five Point Holdings And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures fell, led by Deckers down 9% after mixed results and reduced FY27 guidance. BayCom, ROLR, Trulieve and others also slid premarket.benzinga.com Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42% Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected…
benzinga.com Why Is Moderna Stock Sinking Thursday? Moderna stock plummeted 25% following an alleged ESMO 2026 abstract leak showing lower-than-expected melanoma vaccine Phase 3 efficacy.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market…
benzinga.com FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.benzinga.com TD Cowen Maintains Hold on Moderna, Raises Price Target to $90 TD Cowen analyst Tyler Van Buren maintains Moderna (NASDAQ:MRNA) with a Hold and raises the price target from $40 to $90.
benzinga.com What's Going On With Moderna Stock Monday? Moderna shares are trading higher Monday ahead of detailed Phase 3 melanoma data due Saturday and after BofA raised its price target.
benzinga.com Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today The Nasdaq 100 fell 1.5% at midday Friday as memory chips and AI-debt names sold off, while Fed Chair Warsh declined to rule out an October hike after hot CPI and PPI. WTI held near $96, the 10-year…tradersunion.com Moderna stock tests key support as healthcare rotation supports sentiment Moderna is extending its pullback after failing to hold $230, but the stock is approaching a key technical support zone.
tradersunion.com Moderna and Delta pullback levels draw focus as traders assess healthcare and airline risk Moderna and Delta stocks retreat from highs as investors track pullback levels and reevaluate healthcare and airline sector ...
finance.yahoo.com Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive One melanoma headline turned a $63 stock into a market darling, and Moderna's CEO just told Jim Cramer when patients could ...
cnbc.com Two ‘Best Stocks’ are pulling back from highs. Josh Brown on how to trade them from here The purpose of our The Best Stocks in the Market column is to show you winning trade ideas that you might not otherwise be ...
